Shareholders of Unicycive Therapeutics Encouraged to Join Class Action Suit Before Deadline
Class Action Lawsuit Opportunity for Unicycive Therapeutics Shareholders
On September 15, 2025, The Gross Law Firm issued a call to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to participate in a class action lawsuit. This critical legal action arises from concerns regarding potential misstatements made by the company, affecting investors' decisions and the overall integrity of the market.
Background on Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics for chronic kidney disease and other serious conditions. However, during a specific window, from March 29, 2024, to June 27, 2025, the company allegedly misrepresented important information regarding its compliance with FDA manufacturing requirements and the prospects of its new drug application.
Allegations and Legal Grounds
The lawsuit, which is still unfolding, presents claims that during the designated class period, Unicycive’s executives made materially false statements or omitted crucial information. The allegations are centered around three main points:
1. The assertion that Unicycive could satisfy FDA's manufacturing compliance requirements was overstated.
2. The claims regarding the regulatory prospects for oxylanthanum carbonate were exaggerated.
3. Consequently, public statements made by the company's leadership at the time were deemed misleading, causing investors to suffer losses.
The Importance of Timely Registration
Shareholders who bought shares within the aforementioned class period are encouraged to register their information with The Gross Law Firm. It is important to note that registering as a plaintiff does not require you to take on any significant financial commitments, nor does it obligate you to participate as the lead plaintiff. However, if you wish to be considered for lead plaintiff status, the deadline for registration is October 14, 2025.
By registering, investors will also gain access to a monitoring service that provides updates regarding the status of the case as it progresses through the legal system. This can include crucial timelines, hearing updates, and significant developments related to the lawsuit's outcome.
Why Choose The Gross Law Firm?
The Gross Law Firm is well-known nationally for handling class action cases and stands firm in its mission to advocate for investors. They have successfully represented numerous clients facing similar instances of corporate misrepresentation. The firm’s priority is to ensure that businesses engage in responsible practices and that shareholders receive necessary transparency.
Get Involved
If you are a shareholder of Unicycive Therapeutics Inc. and believe that you have been adversely affected by these alleged misstatements, take action today. Visit this link to register. Your involvement could be essential in holding the company accountable and potentially recovering losses incurred during this troubling period.
Stay informed, and do not miss the deadline to join this important class action lawsuit. The legal team at The Gross Law Firm is ready to assist you in seeking justice for the perceived inadequacies of Unicycive Therapeutics.
On September 15, 2025, The Gross Law Firm issued a call to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to participate in a class action lawsuit. This critical legal action arises from concerns regarding potential misstatements made by the company, affecting investors' decisions and the overall integrity of the market.
Background on Unicycive Therapeutics
Unicycive Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics for chronic kidney disease and other serious conditions. However, during a specific window, from March 29, 2024, to June 27, 2025, the company allegedly misrepresented important information regarding its compliance with FDA manufacturing requirements and the prospects of its new drug application.
Allegations and Legal Grounds
The lawsuit, which is still unfolding, presents claims that during the designated class period, Unicycive’s executives made materially false statements or omitted crucial information. The allegations are centered around three main points:
1. The assertion that Unicycive could satisfy FDA's manufacturing compliance requirements was overstated.
2. The claims regarding the regulatory prospects for oxylanthanum carbonate were exaggerated.
3. Consequently, public statements made by the company's leadership at the time were deemed misleading, causing investors to suffer losses.
The Importance of Timely Registration
Shareholders who bought shares within the aforementioned class period are encouraged to register their information with The Gross Law Firm. It is important to note that registering as a plaintiff does not require you to take on any significant financial commitments, nor does it obligate you to participate as the lead plaintiff. However, if you wish to be considered for lead plaintiff status, the deadline for registration is October 14, 2025.
By registering, investors will also gain access to a monitoring service that provides updates regarding the status of the case as it progresses through the legal system. This can include crucial timelines, hearing updates, and significant developments related to the lawsuit's outcome.
Why Choose The Gross Law Firm?
The Gross Law Firm is well-known nationally for handling class action cases and stands firm in its mission to advocate for investors. They have successfully represented numerous clients facing similar instances of corporate misrepresentation. The firm’s priority is to ensure that businesses engage in responsible practices and that shareholders receive necessary transparency.
Get Involved
If you are a shareholder of Unicycive Therapeutics Inc. and believe that you have been adversely affected by these alleged misstatements, take action today. Visit this link to register. Your involvement could be essential in holding the company accountable and potentially recovering losses incurred during this troubling period.
Stay informed, and do not miss the deadline to join this important class action lawsuit. The legal team at The Gross Law Firm is ready to assist you in seeking justice for the perceived inadequacies of Unicycive Therapeutics.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.